{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:22:55Z","timestamp":1788841375381,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016724","name":"Post Graduate Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["5\/4\/7-2\/Nephro\/2021-NCD-II"],"award-info":[{"award-number":["5\/4\/7-2\/Nephro\/2021-NCD-II"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ekir.2025.08.018","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T01:32:20Z","timestamp":1755826340000},"page":"3785-3795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy"],"prefix":"10.1016","volume":"10","author":[{"given":"Raja","family":"Ramachandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyita","family":"Bharati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Sahay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indranil","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur","family":"Sain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhjot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Prabhahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritambhra","family":"Nada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita","family":"Divyaveer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbir","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.08.018_bib1","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.018_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ekir.2025.08.018_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.08.018_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1053\/j.ajkd.2023.02.003","article-title":"KDOQI US commentary on the 2021 KDIGO clinical practice guideline for the management of glomerular diseases","volume":"82","author":"Beck","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.08.018_bib5","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.018_bib6","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.08.018_bib7","first-page":"347","article-title":"Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis?","volume":"62","author":"Wetzels","year":"2004","journal-title":"Neth J Med"},{"key":"10.1016\/j.ekir.2025.08.018_bib8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.018_bib9","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.08.018_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.12283","article-title":"European survey on clinical practice of detecting and treating T-cell mediated kidney transplant rejection","volume":"37","author":"Koshy","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.ekir.2025.08.018_bib11","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fernandez-Juarez","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.08.018_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.08.018_bib13","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.018_bib14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.08.018_bib15","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.ekir.2022.07.002","article-title":"Challenges in diagnosis and management of glomerular disease in resource-limited settings","volume":"7","author":"Ramachandran","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.08.018_bib16","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.kint.2017.12.019","article-title":"Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab","volume":"93","author":"van de Logt","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.08.018_bib17","series-title":"Economic poverty trends: global, regional and national","year":"2023"},{"key":"10.1016\/j.ekir.2025.08.018_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/nep.13953","article-title":"Treatment preferences for primary membranous nephropathy: results of a multinational survey among nephrologists in the South Asia Pacific region","volume":"27","author":"Bose","year":"2022","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2025.08.018_bib19","doi-asserted-by":"crossref","DOI":"10.15171\/jnp.2019.25","article-title":"Efficacy and safety of a modified- \u2018modified Ponticelli\u2019 regimen for treatment of primary membranous nephropathy","volume":"8","author":"Rao","year":"2019","journal-title":"J Nephropathol"},{"key":"10.1016\/j.ekir.2025.08.018_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfac067.061","article-title":"Intravenous cyclophosphamide for high-risk primary PLA2R-positive membranous nephropathy","author":"Stefan","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.08.018_bib21","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/ckj\/sfw152","article-title":"Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy","volume":"10","author":"Mathrani","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.08.018_bib22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.34067\/KID.0002802020","article-title":"Substitution of oral for intravenous cyclophosphamide in membranous nephropathy","volume":"1","author":"Luzardo","year":"2020","journal-title":"Kidney360"},{"key":"10.1016\/j.ekir.2025.08.018_bib23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/nep.12955","article-title":"Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy","volume":"23","author":"Kanigicherla","year":"2018","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2025.08.018_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1440-1797.2010.01427.x","article-title":"Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: a single centre\u2019s retrospective study","volume":"16","author":"Yuan","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2025.08.018_bib25","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ekir.2017.02.004","article-title":"Two-year follow-up study of membranous nephropathy treated with tacrolimus and corticosteroids versus cyclical corticosteroids and cyclophosphamide","volume":"2","author":"Ramachandran","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.08.018_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/nep.12569","article-title":"Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: randomized control trial","volume":"21","author":"Ramachandran","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2025.08.018_bib27","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1681\/ASN.V93444","article-title":"A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy","volume":"9","author":"Ponticelli","year":"1998","journal-title":"J Am Soc Nephrol"}],"updated-by":[{"DOI":"10.1016\/j.ekir.2025.103768","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000}}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925005248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925005248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:50:50Z","timestamp":1783025450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925005248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2468024925005248"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.08.018","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized Controlled Trial on the Efficacy of Reduced-Dose Cyclical Corticosteroids and Cyclophosphamide in Primary Membranous Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.08.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}